4D Molecular Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $319.1M | $153.0M |
| FY2022 | — | $231.3M | $52.4M |
| FY2023 | — | $307.8M | $249.1M |
| FY2024 | — | $510.6M | $149.3M |
| FY2025 | — | $505.7M | $60.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $319.1M | $153.0M |
| FY2022 | — | $231.3M | $52.4M |
| FY2023 | — | $307.8M | $249.1M |
| FY2024 | — | $510.6M | $149.3M |
| FY2025 | — | $505.7M | $60.2M |